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Interdigitating dendritic cell sarcoma (IDCS) is a very rare disease around the world and its prognosis is known to be 
aggressive. This reports a case diagnosed as IDCS of the axillary region treated in Soonchunhyang University Hospital. A 
57-year-old female visited Soonchunhyang University Hospital with a left axillary mass. The mass was hard and fixed. 
Computed tomography observed a 7 cm lymph node at the left axilla, and core biopsy suspected sarcoma. In another study, 
there was no specific finding except the axillary lesion. Left axillary lymph node dissection (level I, II) was conducted and the 
pathologic report finally showed IDCS. The patient was treated with only radiotherapy and followed up without recurrence 
for 13 months up to now. IDCS is a very rare sarcoma that is hard to diagnose and progresses fast. Thus, treatment is very 
difficult. Proper treatment can be better established after more experiences.
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INTRODUCTION
Dendritic cells are arachnoid immune accessory cells 
originating on hematopoietic stem cells, and sarcoma on 
dendritic cells is divided into various subtypes including 
Langerhans cell sarcoma, interdigitating dendritic cell sar-
coma (IDCS), follicular dendritic cell sarcoma, dermal 
dendrocyte sarcoma, interstitial dendritic cell sarcoma 
and veiled cell sarcoma [1]. Most IDCS occurs in the lymph 
node (particularly in the collum, the mediastinum and ax-
illa) and around one third of it is found in other organs ex-
cept the lymph node. For the organs, the liver is observed 
most frequently, while others are the spleen, the skin, the 
lung, the rhinopharynx, the small intestine and the breast 
[1,2].
The incidence rate of IDCS was reported to be slightly 
higher in males than in females (1:1.4), and its mean age at 
onset was about 46 years but it was shown in all age groups 
(14 to 80 years) [3]. Its prognosis is highly aggressive. 
Against this background, a case diagnosed as IDCS of 
the axilla and treated in Soonchunhyang University 
Hospital is reported.Interdigitating dendritic cell sarcoma occured alone in axilla
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Fig. 1. Axillary lymph node enlargement at computed tomography. (A) Arrow shows about 7 cm sized lymph node. (B) Arrow shows about 
2 cm sized lymph node around main.
CASE REPORT
A 57-year-old female visited Soonchunhyang University 
Hospital with a left axillary mass palpated for the last two 
months as a chief complaint. The first physical examination 
found no specific abnormality such as pain or burning sen-
sation except the palpable mass in the left axilla. The mass 
was hard and fixed.
Chest computed tomography (CT) showed an approx-
imately 7 cm mass clearly observed in the left axillary re-
gion and several lymph nodes enlarged to be 2 cm around 
the mass (Fig. 1).
Breast ultrosonography and mammography were per-
formed first to determine whether it was breast cancer or 
not but revealed no mass in the breast and no calcification 
lesion, respectively. Next, core biopsy found an abnormal-
ity suspected to be sarcoma in the lymph node, so addi-
tional tests were conducted to check its primary site.
Colonoscopy and gastroscopy revealed no abnormality 
and abdomen CT also did not reveal a primary site. Bone 
marrow biopsy to examine bone marrow involvement re-
corded a negative result. Lastly, positron emission tomog-
raphy (PET) CT also found no specific abnormality except 
the increase of 18-fluoro-deoxyglucose in the left axillary 
region (Fig. 2). 
The patient underwent left axillary lymph node dis-
section (level I, II) as she was thought to have sarcoma 
originating in the axillary lymph node. Permanent patho-
logic report finally diagnosed it as IDCS originating in the 
axillary lymph node (Fig. 3). The microscopy showed 
ill-defined, paracortically proliferating irregular nests of 
spindle to ovoid cells in fascicles. The remaining follicles 
were frequently seen. The tumor cells showed mild to 
moderate nuclear atypia. Mitosis was rarely seen and ne-
crosis was not present. Immunohistochemistry showed 
that S-100 protein, vimentin, CD99, CD68 and cyclin D1 
were positive and CD34, CD20, CD21, CD23, CD3, 
HMB-45, desmin and melanin A were negative. Ki-67 or a 
tumor marker was around 10%.
After the surgery, the patient was treated only with ra-
diotherapy not chemotherapy as adjuvant therapy and re-
currence has not been observed for thirteen months up to 
now.
DISCUSSION
Interdigitating dendritic cells are an antigen presenting 
cells observed on T cells of the peripheral lymphoid tis-
sues, and sarcoma originating on it is very rare and is his-
tologically similar with B cell lymphoma or T cell lympho-
ma and other spindle cell neoplasm [2].
Due to this similarity, it is hard to distinguish through hem-
atoxylin and eosin staining, which is conducted frequently 
for pathologic diagnoses [1]. So, immunohistochemistry is 
necessary to confirm IDCS. For the sarcoma, S-100 and 
CD45RB protein, HLA-DR and vimentin are positive and 
CD1a, CD21, and CD35 protein are negative while CD68 is 
positive or negative. Another property in differentiating it is 
its structural characteristics. It has been reported that inter-
digitating cytoplasmic processes or one characteristic of in-
terdigitating dendritic cells existed on the surface of cells but Sun Wook Han, et al.
332 thesurgery.or.kr
Fig. 2. Positron emission tomography shows increase of 18-fluoro-deoxyglucose in left axillary region.
Fig. 3.  Microscopic lymph node finding in axillary interdigitating dendritic cell sarcoma (IDCS). (A) Axillary IDCS (H&E, ×400). (B) S-100 
protein (immunohistochemical stain, ×400).
Birbeck granules were insufficient [4]. There is no biomarker 
specific only to IDCS [2].  
However, despite these characteristics, it is very hard to 
distinguish it from malignant melanoma because malig-
nant tumors also show a positive result in S-100 protein 
and CD68. So, IDCS cannot be diagnosed only with the re-
sults of immunohistochemistry and should be done by 
considering clinical results of all examinations [2]. 
In this study, the postoperative pathologic report re-
corded that S-100 protein, CD68 and vimentin were pos-
itive while CD21 and melanin A were negative. But, the 
possibility of metastatic melanoma could not be excluded 
completely. Thus, visual inspection of the total skin, abdo-
men CT, gastroscopy, colonoscopy and PET CT were con-
ducted finding no possibility of melanoma. 
IDCS does not generally provoke any specific symptom. 
Its symptoms are similar with those of lymphadenitis and 
can include fever and constitutional symptoms such as de-Interdigitating dendritic cell sarcoma occured alone in axilla
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creased body weight in some cases [2].
Although any guideline to treat IDCS has not been estab-
lished as it is very rare, a surgical excision is primarily ap-
plied because its lesion is limited to the site of origin in 
most cases [1-4]. 
As adjuvant therapy after the surgery, chemotherapy 
and radiotherapy can be considered. Kairouz et al. [5] in-
sisted that postoperative radiotherapy increased disease 
free survival, but it has not been accepted as a standard 
treatment.
Chemotherapy also was reported to be effective in some 
studies, but it was not accepted as an infallible therapy.
Efune et al. [6] showed that ABVD (adriamycin, bleo-
mycin, vinblastine, dacarbazine) achieved complete 
remission. However, Olnes et al. [7] insisted that a good 
prognosis could be obtained only with ABVD chemo-
therapy without surgical treatment. But, De Pas et al. [4] 
found through literature review that many cases of IDCS 
were treated only with surgery even though its recurrence 
rate was actually 40% and the rate was not significantly 
different from the recurrence rate (32.6%) after adding 
chemotherapy and radiotherapy to the surgical treatment, 
so the adjuvant therapy did not reduce the recurrence.
Although large scale studies are necessary to prove its 
effect, verifying the effect is considered not to be easy due 
to realistic difficulties.
In Korea, IDCS in the tonsil and in the pleura was 
reported. While IDCS in the tonsil led to nearly complete 
remission after four time CHOP (cyclophosphamide, dox-
orubicin, vincristine, prednisolone) chemotherapy [8], the 
patient with IDCS in the pleura died in three months de-
spite two time CHOP and one time IMEP (ifosfamide, me-
thotrexate, etoposide, prednisolone) [9].
In Soonchunhyang University Hospital, postoperative 
chemotherapy for IDCS was not performed and the pa-
tient in this case has been followed up after radiotherapy. 
There has been no evidence of recurrence for thirteen 
months until now and she is followed up regularly. 
For the course after treatment, as mentioned before, 
IDCS is very aggressive and metastasis at diagnosis is 
found more frequently than follicular dendritic cell sarco-
ma, so its prognosis is known to be very aggressive [4].
According to previous reports, average survival time is 
around nine months after postoperative chemotherapy 
and radiotherapy and survival of over five years is quite 
rare [2].
One of the factors affecting its prognosis was found to 
be the size of the sarcoma. Over 5 cm IDCS recorded a sig-
nificantly higher recurrence rate than smaller ones (50% 
vs. 11%). Therefore, its size is considered to be very critical. 
Except that, mitotic count and necrosis were also reported 
to influence its prognosis. In addition, the authors of the 
report suggested that higher expression rate of Ki-67 could 
produce a negative effect on the prognosis but that needs 
to be studied more [4]. 
In conclusion, IDCS is a very rare sarcoma that is hard to 
diagnose and progresses fast; treating it is very difficult. 
Therefore, a proper treatment guideline can be established 
after more experiences and treatments are accumulated.
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